跳至主要内容
临床试验/NCT01308801
NCT01308801已完成不适用

Benefice Assessment of Repetitive Transcranial Magnetic Stimulation Used as an Additional Procedure to Rehabilitation Exercises in Patients Suffering From Fibromyalgia

University Hospital, Grenoble2 个研究点 分布在 1 个国家目标入组 42 人开始时间: 2011年4月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
42
试验地点
2
主要终点
Change from baseline in pain Visual Analog Scale (VAS) at 14 weeks of treatment

研究概览

简要总结

The purpose of this study is to determine the analgesic effectiveness of Repetitive Transcranial Magnetic Stimulation (rTMS) used as an additional procedure to rehabilitation exercises in patient suffering from fibromyalgia.

A double blind clinical trial with two randomized parallel groups:

  • Placebo rTMS and rehabilitation exercise
  • Active rTMS and rehabilitation exercise

详细描述

Fibromyalgia is the most frequent chronic diffuse painful disease (3 to 4% of the general population).

Analgesic drugs are widely used in fibromyalgia, pain being the main symptom. However the effectiveness of analgesic drugs is often insufficient.

Among non-drug therapies, rehabilitation exercise plays an important role with a special interest in terms of the quality of life, strain and pain.

More recently the Transcranial Magnetic Stimulation effects have been evaluated in patients suffering from fibromyalgia with a statistically significative analgesic effect.

Both rehabilitation exercise and Transcranial Magnetic Stimulation (rTMS) have shown their respective analgesic effectiveness in fibromyalgia. It now seems important to evaluate the combination of these two therapies.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •primary fibromyalgia according to the American College of Rheumatology
  • •no contraindication to rehabilitation exercise
  • •pain with VAS > 4 during at least six months
  • •FIQ score > 50
  • •no change in drug therapy over the last month
  • •affiliation to French Health Service

排除标准

  • •BMI > 35kg/m²
  • •patient who has already benefited from rTMS
  • •rTMS contraindication
  • •restless legs symptom
  • •patient suffering from major depression
  • •patient suffering from inflammatory rheumatism, autoimmune disease, other chronic pain pathology
  • •sleep apnea syndrome
  • •no contraindication to rTMS or MRI
  • •pregnant women

研究组 & 干预措施

active rTMS + rehabilitation exercise

Experimental

14 weeks of active repetitive transcranial magnetic stimulation associated with rehabilitation exercise

干预措施: active rTMS + rehabilitation exercise (Device)

placebo rTMS + rehabilitation exercise

Placebo Comparator

14 weeks of placebo repetitive transcranial magnetic stimulation associated with rehabilitation exercise

干预措施: placebo rTMS+ rehabilitation exercise (Device)

结局指标

主要结局

Change from baseline in pain Visual Analog Scale (VAS) at 14 weeks of treatment

时间窗: Daily average VAS at baseline, week 2, week 4, week 8, week 14

Patient will note down each day the VAS for the last 24 hours.

次要结局

  • Change from base line in quality of life at 14 weeks and 26 weeks(At the beginning of the program, at the end (14 weeks), and 26 weeks after the end of the program)
  • Change from base line in depression assessment at 14 weeks and 26 weeks(at the beginning of the program, at the end (14 weeks), and 26 weeks after the end of the program)
  • Change from baseline in Covi's anxiety scale(at the beginning of the program, at the end (14 weeks), and 26 weeks after the end of the program)
  • Change from baseline in sleep quality at 14 weeks abd 26 weeks(At the beginning of the program, at the end (14 weeks), and 26 weeks after the end of the program)
  • Change from baseline in neuromuscular fatigability at 14 weeks and 26 weeks(At the beginning of the program, at the end (14 weeks), and 26 weeks after the end of the program)
  • Change from baseline in cardiac variability at 14 weeks and 26 weeks(At the beginning of the program, at the end (14 weeks), and 26 weeks after the end of the program)
  • Evolution of the analgesic effect after the end of the program(Daily average VAS at the end (14 weeks) and 26 weeks after the end of the program)

研究者

发起方
University Hospital, Grenoble
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验